BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma (329)
BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study
Sponsor: Brown University
Terminated
lack of response to study therapy
This PHASE1/PHASE2 trial investigates GBM and Glioblastoma and is currently terminated or withdrawn. Brown University leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
-
Mar 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Feb 2019 — Sep 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brown University
- Merrimack Pharmaceuticals
- Rhode Island Hospital
For direct contact, visit the study record on ClinicalTrials.gov .